New Test for Lp(a) Allows More Accurate LDL-Cholesterol Results

March 18, 2022

A new study has drawn attention to inaccurate measurement of LDL-cholesterol levels in some patients with current assays, which could lead to incorrect therapeutic approaches.

The patient groups most affected are those with high levels of the lipoprotein Lp(a), in whom LDL-cholesterol levels are being overestimated in current laboratory tests, the authors say.

"Current laboratory assays all have the limitation that they cannot measure or report LDL cholesterol accurately. They are actually measuring the combination of LDL and Lp(a)," senior study author Sotirios Tsimikas, MD, University of California, San Diego, explained to | Medscape Cardiology.   

"While this may not matter much in individuals with normal Lp(a) levels, in those with elevated Lp(a), the Lp(a) cholesterol may constitute a substantial proportion of the reported LDL cholesterol, and the actual LDL-cholesterol levels could be much lower that the value the lab is telling us," he said.

Tsimikas gave the example of a patient with an LDL-cholesterol lab measurement of 75 mg/dL. "If that patient has an Lp(a) level of zero then they do actually have an LDL level of 75. But as the Lp(a) increases, then the proportion of the result accounted for by LDL cholesterol decreases. So, if a patient with a measured LDL cholesterol of 75 has an Lp(a)-cholesterol level of 20, then their actual LDL level is 55."

Tsimikas said it is important to know levels of both lipoproteins individually, so the correct therapeutic approach is used in situations where the Lp(a) cholesterol might be elevated.

“By understanding the actual values of LDL cholesterol and Lp(a) cholesterol, this will allow us to personalize the use of cholesterol-lowering medications and decide where to focus treatment. In the patient with a high level of Lp(a), their residual risk could be coming from Lp(a) cholesterol and less so from LDL cholesterol," he added. "As we develop drugs to lower Lp(a), this patient might be better off on one of these rather than increasing efforts to lower LDL cholesterol, which might already be at goal."

The study was published in the March 22 issue of the Journal of the American College of Cardiology.

Tsimikas noted that Lp(a) is now accepted as a genetic, independent, causal risk factor for cardiovascular disease, but current LDL-lowering drugs do not have much effect on Lp(a).

"Lp(a) can be lowered a little with niacin and PCSK9 inhibitors, but both have a quite a weak effect, and statins increase Lp(a). However, there are now multiple RNA-based therapeutics specifically targeting Lp(a) in clinical development," he said.

At present, Lp(a) cholesterol has to be mathematically estimated, most commonly with the Dahlén formula, because of the lack of a validated, quantitative method to measure Lp(a) cholesterol, Tsimikas says.  

For the current study, the researchers used a novel, quantitative, sensitive, method to directly measure Lp(a) cholesterol, and then applied this method to data from a recent study with the one of the new Lp(a)-lowering drugs in development — pelacarsen — which was conducted in patients with elevated Lp(a) levels.

Results showed that direct Lp(a)-cholesterol assessment, and subtracting this value from the laboratory LDL-cholesterol value, provides a more accurate reflection of the baseline and change in LDL cholesterol, the authors report. In the current study, corrected LDL cholesterol was 13 to 16 mg/dL lower than laboratory-reported LDL cholesterol.

Using the corrected LDL-cholesterol results, the study showed that pelacarsen significantly decreases Lp(a) cholesterol, with neutral to modest effects on LDL.

The study also suggests that the current method of calculating Lp(a) cholesterol, and then deriving a corrected LDL cholesterol — the Dahlén formula — is not accurate. 

"The Dahlén formula relies on the assumption that Lp(a) cholesterol is universally a fixed 30% of Lp(a) mass, but this usually isn't the case. The Dahlén formula needs to be discontinued. It can be highly inaccurate," Tsimikas said.  

Important Implications

In an accompanying editorial, Guillaume Paré, MD, Michael Chong, PhD, and Pedrum Mohammadi-Shemirani, BSc, McMaster University, Hamilton, Ontario, Canada, say the current findings have three important clinical implications.

"First, they provide further proof that in individuals with elevated Lp(a), the contribution of Lp(a)-cholesterol to LDL-cholesterol is non-negligible using standard assays, with 13-16 mg/dL lower LDL-cholesterol post-correction."

Secondly, the editorialists point out that these new findings confirm that the effect of Lp(a) inhibitors is likely to be mostly confined to Lp(a), "as would be expected."

Finally, "and perhaps more importantly, the authors highlight the need to improve clinical reporting of lipid fractions to properly treat LDL-cholesterol and Lp(a) in high-risk patients," they note.

"The report paves the way for future studies investigating the clinical utility of these additional measurements to initiate and monitor lipid-lowering therapy," they conclude.

The clinical trial was funded by Ionis Pharmaceuticals, and the direct Lp(a)-cholesterol measurements were funded by Novartis through a research grant to the University of California San Diego (UCSD). Tsimikas is an employee of Ionis Pharmaceuticals and of the University of California, San Diego; and is a cofounder of Covicept Therapeutics. He is also a coinventor and receives royalties from patents owned by UCSD on oxidation-specific antibodies and on biomarkers related to oxidized lipoproteins, and is a cofounder and has equity interest in Oxitope, Inc, and Kleanthi Diagnostics.

J Am Coll Cardiol. 2022;79:1035-1046, 1047-1049. Full text, Editorial


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.